Roth Capital Lowers Cytori Therapeutics Price Target to $3.50 (CYTX)
Equities research analysts at Roth Capital reduced their price objective on shares of Cytori Therapeutics (NASDAQ:CYTX) from $10.00 to $3.50 in a research note issued to investors on Wednesday. Roth Capital’s price objective points to a potential upside of 96.63% from the stock’s previous close.
Shares of Cytori Therapeutics (NASDAQ:CYTX) traded down 14.76% during mid-day trading on Wednesday, hitting $1.79. The stock had a trading volume of 2,465,073 shares. Cytori Therapeutics has a 52 week low of $2.00 and a 52 week high of $3.93. The stock has a 50-day moving average of $2.24 and a 200-day moving average of $2.53. The company’s market cap is $135.1 million.
Cytori Therapeutics (NASDAQ:CYTX) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.14). The company had revenue of $1.03 million for the quarter, compared to the consensus estimate of $2.87 million. Analysts expect that Cytori Therapeutics will post $-0.42 EPS for the current fiscal year.
A number of other firms have also recently commented on CYTX. Analysts at Ascendiant Capital Markets downgraded shares of Cytori Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday. They now have a $4.00 price target on the stock. Analysts at Maxim Group cut their price target on shares of Cytori Therapeutics from $10.00 to $9.00 in a research note on Tuesday, May 13th. They now have a “buy” rating on the stock.
Cytori Therapeutics, Inc develops cell therapies based on autologous adipose-derived stem and regenerative cells (NASDAQ:CYTX) to treat cardiovascular disease and repair soft tissue defects.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.